id	等位基因	注释文本
1110	*2xN	The CYP2D62xN alleles (2x2 and 2x鈮?) are assigned as increased function alleles by CPIC. Patients carrying a 2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a 2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a 2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.
1109	*2	The CYP2D62 allele is assigned as a normal function allele by CPIC. Patients carrying the 2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.
1108	*1xN	The CYP2D61xN alleles (1x2 and 1x鈮?) are assigned as increased function alleles by CPIC. Patients carrying a 1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a 1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a 1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.
1107	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.

id	证据的ID	总结
193	1183623203	CYP2D6 2/2xN is associated with increased risk of cns depression or Death when treated with codeine in infants as compared to CYP2D6 1/1xN.
192	1183682365	CYP2D6 1/2xN is associated with risk of Death when treated with codeine in children with adenotonsillectomy for obstructive sleep apnea syndrome.
191	1183680580	CYP2D6 *1xN is associated with severity of abdominal pain when treated with codeine.
190	1183632396	CYP2D6 1/2xN + 2/2xN are associated with increased opioid related adverse events ( immediate pain relief from codeine but stopped taking it due to dizziness and constipation) when treated with codeine in women as compared to CYP2D6 1/1.
189	1183623194	CYP2D6 1/1xN is associated with Life-threatening opioid intoxication when treated with codeine as compared to CYP2D6 1/1.
188	1183618114	CYP2D6 1xN is associated with Respiratory Insufficiency when treated with codeine as compared to CYP2D6 1/*1.
187	1183617941	CYP2D6 1/2xN is associated with increased risk of Drug Toxicity when treated with codeine, hydrocodone or oxycodone in healthy individuals as compared to CYP2D6 1/1.
186	1183684089	CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain.
185	1183682358	CYP2D6 ultra-metabolizer phenotype is associated with increased risk of Death or Severe Respiratory Depression when treated with codeine in children with adenotonsillectomies for obstructive sleep apnea syndrome.
184	PA166104970	Annotation of DPWG Guideline for codeine and CYP2D6
183	PA166104996	Annotation of CPIC Guideline for codeine and CYP2D6

id	类型	评论
1592	Update	Added DPWG guideline as evidence
1591	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1590	Update	Minor edits to phenotype descriptions
1589	Update	Rewrote phenotype descriptions and added CPIC guideline
1588	Create	Created

最新招商产品更多>>